Allarity Therapeutics, Inc. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
Allarity Therapeutics, Inc. (ALLR) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of $15.18 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-15.
Financial Statements › Cash Flow › Change in Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2026-05-15
- Allarity Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2026-03-31 was $15.18M, a 79.53% increase year-over-year.
- Allarity Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2025-03-31 was $8.46M.
- Allarity Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2024-03-31 was -$19.00K.
- Allarity Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2023-03-31 was -$2.04M.
- Allarity Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2025 was -$4.18M, a 121.84% decline from fiscal 2024.
- Allarity Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2024 was $19.14M.
- Allarity Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2023 was -$1.75M.
- Allarity Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2022 was -$17.34M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month as first filed | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month as first filed | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|---|---|
| 2026-03-31 | $15.18M 10-Q · filed 2026-05-15 | |||||
| 2025-12-31 | -$4.18M 10-K · filed 2026-03-30 | |||||
| 2025-09-30 | -$689.00K 10-Q · filed 2025-11-14 | |||||
| 2025-06-30 | $411.00K 10-Q · filed 2025-08-15 | |||||
| 2025-03-31 | $8.46M 10-Q · filed 2026-05-15 | |||||
| 2024-12-31 | $19.14M 10-K · filed 2026-03-30 | |||||
| 2024-09-30 | $18.41M 10-Q · filed 2025-11-14 | |||||
| 2024-06-30 | $18.99M 10-Q · filed 2025-08-15 | |||||
| 2024-03-31 | -$19.00K 10-Q · filed 2025-05-09 | -$107.00K 10-Q · filed 2024-05-14 | ||||
| 2023-12-31 | -$1.75M 10-K · filed 2025-03-31 | |||||
| 2023-09-30 | -$600.00K 10-Q · filed 2024-11-14 | |||||
| 2023-06-30 | -$1.67M 10-Q · filed 2024-08-05 | |||||
| 2023-03-31 | -$2.04M 10-Q · filed 2024-05-14 | |||||
| 2022-12-31 | -$17.34M 10-K · filed 2024-03-08 | |||||
| 2022-09-30 | -$15.87M 10-Q · filed 2023-11-14 | |||||
| 2022-06-30 | -$11.46M 10-Q · filed 2023-08-14 | |||||
| 2021-09-30 | $5.81M 10-Q/A · filed 2022-05-17 | $5.64M 10-Q · filed 2021-11-23 | ||||
| 2020-09-30 | -$1.48M 10-Q/A · filed 2022-05-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B |